Xeligekimab (GR 1501) is an anti-human interleukin 17A (IL-17A) humanized monoclonal antibody. Xeligekimab inhibits the pro-inflammatory cascade[1].
References
[1] Sen R, et, al. Current treatment and molecular targets for axial spondyloarthritis: Evidence from randomized controlled trials. Curr Opin Pharmacol. 2022 Dec;67:102307. DOI:10.1016/j.coph.2022.102307